The continuing value of mesalazine as first-line therapy for patients with moderately active ulcerative colitis

Overview of attention for article published in Frontiers in Gastroenterology, June 2024

Altmetric Badge

Mentioned by

So far, Altmetric has seen 1 X post from an account with 3,043 followers.

New Research: The continuing value of mesalazine as first-line therapy for patients with moderately active ulcerative colitis https://t.co/qTprBIBl2Y #FrontiersIn #Gastroenterology

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.